Zealand Pharma As Stock Beta
| ZEAL Stock | DKK 626.00 15.00 2.45% |
Zealand Pharma AS fundamentals help investors to digest information that contributes to Zealand Pharma's financial success or failures. It also enables traders to predict the movement of Zealand Stock. The fundamental analysis module provides a way to measure Zealand Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zealand Pharma stock.
Zealand |
Zealand Pharma AS Company Beta Analysis
Zealand Pharma's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Zealand Pharma Beta | 0.95 |
Most of Zealand Pharma's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zealand Pharma AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Zealand Pharma AS has a Beta of 0.9511. This is 10.59% higher than that of the Healthcare sector and 31.58% lower than that of the Biotechnology industry. The beta for all Denmark stocks is notably lower than that of the firm.
Zealand Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zealand Pharma's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zealand Pharma could also be used in its relative valuation, which is a method of valuing Zealand Pharma by comparing valuation metrics of similar companies.Zealand Pharma is currently under evaluation in beta category among related companies.
Zealand Pharma returns are very sensitive to returns on the market. As the market goes up or down, Zealand Pharma is expected to follow.
Zealand Fundamentals
| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (3.82) % | |||
| Current Valuation | 10.33 B | |||
| Shares Outstanding | 51.28 M | |||
| Shares Owned By Insiders | 0.07 % | |||
| Shares Owned By Institutions | 56.21 % | |||
| Price To Earning | 12.66 X | |||
| Price To Book | 27.77 X | |||
| Price To Sales | 36.73 X | |||
| Revenue | 292.57 M | |||
| Gross Profit | 173.75 M | |||
| EBITDA | (982.6 M) | |||
| Net Income | (1.02 B) | |||
| Cash And Equivalents | 1.28 B | |||
| Cash Per Share | 29.66 X | |||
| Total Debt | 647.91 M | |||
| Debt To Equity | 0.10 % | |||
| Current Ratio | 4.19 X | |||
| Book Value Per Share | 7.91 X | |||
| Cash Flow From Operations | (1.21 B) | |||
| Earnings Per Share | (23.13) X | |||
| Price To Earnings To Growth | 0.31 X | |||
| Target Price | 243.75 | |||
| Number Of Employees | 203 | |||
| Beta | 0.95 | |||
| Market Capitalization | 11.16 B | |||
| Total Asset | 2.07 B | |||
| Retained Earnings | 154 M | |||
| Working Capital | 463 M | |||
| Current Asset | 517 M | |||
| Current Liabilities | 54 M | |||
| Z Score | 10.2 | |||
| Net Asset | 2.07 B |
About Zealand Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zealand Pharma AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zealand Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zealand Pharma AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zealand Pharma AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Complementary Tools for Zealand Stock analysis
When running Zealand Pharma's price analysis, check to measure Zealand Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zealand Pharma is operating at the current time. Most of Zealand Pharma's value examination focuses on studying past and present price action to predict the probability of Zealand Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zealand Pharma's price. Additionally, you may evaluate how the addition of Zealand Pharma to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |